Genetically engineered immune cells target cancer cells that

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

Related Keywords

United States , Monical Guzman , Gail Roboz , Emily Henderson , Nature Communications , Division Of Hematology Medical Oncology , Presbyterian Weill Cornell Medical Center , Meyer Cancer Center At Weill Cornell Medicine , Translational Leukemia Program At Weill Cornell Medicine , Weill Cornell , Medical Oncology , Edward Meyer Cancer Center , Weill Cornell Medical , Translational Leukemia Program , Weill Cornell Medicine , Meyer Cancer Center , Leukemia , Acute Myeloid Leukemia , Ntigen , Flood , Blood Cancer , Dancer , Fell , Clinical Trial , Hematology , Laboratory , Medicine , Olecule , Myeloid Leukemia , Ncology , Reclinical , Eceptor , Stem Cells ,